Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
RESEARCH TOOLSreports
Holding ENTA?
Track your performance easily
ENTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.70 - $17.80
Previous Close$6.28
Volume655.72K
Average Volume (3M)274.41K
Market Cap
$124.20M
Enterprise Value-$68.52M
Total Cash (Recent Filing)$248.19M
Total Debt (Recent Filing)$55.47M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Feb 05, 2025EPS Estimate
-$1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.49
Shares Outstanding21,194,326
10 Day Avg. Volume639,034
30 Day Avg. Volume274,409
Standard Deviation0.16
R-Squared0.02
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.04
Price to Sales (P/S)1.73
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.99
Enterprise Value/Gross Profit-1.01
Enterprise Value/Ebitda0.62
Forecast
1Y Price Target
$17.29Price Target Upside175.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Enanta Pharmaceuticals News
PremiumCompany Announcements
Enanta Pharmaceuticals Reports Promising Results for Pediatric RSV DrugBulls Say, Bears Say
Bulls Say
Drug EfficacyEDP-323's safety in the challenge trial was consistent with Phase 1, with no serious adverse events or discontinuations due to treatment.
Financial PositionEnanta ended F4Q24 with a cash position of approximately $248 million, which should fund operations into fiscal 2027.
RSV TherapeuticsProblems with RSV vaccines would increase the need for safe and effective therapeutics, potentially benefiting Enanta.
Bears Say
Clinical TrialsRisks to the investment thesis and target price include clinical trial failures of planned and ongoing studies.
Financial PerformanceEnanta reported fiscal 4Q/FY24 financials with total royalty revenues of approximately $14.6 million for Mavyret in HCV, which were about 25% below the estimate and approximately 19% below FactSet consensus.
Regulatory ApprovalFailure to secure regulatory approval of EDP-938, EDP-323, or EDP-514 could impact the company negatively.
---
Ownership Overview
6.90% Insiders
14.11% Mutual Funds
31.92% Other Institutional Investors
35.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $5.70 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Currently, no data Available
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Feb 05, 2025 which is in 45 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Nov 25, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$1.161 by -$0.199.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -$1.27.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,194,326 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.36 in its last earnings report, missing expectations of -$1.161. Following the earnings report the stock price went down -4.994%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 22M.
---
Enanta Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.29 (175.32% Upside)
$17.29 (175.32% Upside)
Hedge Fund Trend
Increased
By 13.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $127.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.29%
12-Months-Change
Fundamentals
Return on Equity
-67.17%
Trailing 12-Months
Asset Growth
-16.82%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Company Deck
---
ENTA Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with significant advancements in the RSV and immunology programs and a stable financial position. However, it also highlighted challenges with a decline in revenue, increased net loss, and slower enrollment in the RSVPEDs study.Read More>---
ENTA Stock 12 Month Forecast
Average Price Target
$17.29
▲(175.32% Upside)
Technical Analysis
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
8/19 ratings generated profit
1 Year Average Return
+1.86%
assigned a buy rating 9 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +1.86% per trade.
---